invoX Pharma Limited (“invoX”), a research-driven global biopharmaceutical company with an advancing pipeline of innovative products, and Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug discovery company, have entered a new strategic collaboration to combine Insilico’s computational services and AI with invoX’s drug discovery, development and data science capabilities. The aim of the collaboration is to enhance research and development activities for invoX by identifying potential novel indications for pipeline assets in oncology.
invoX Pharma Limited (“invoX”), a research-driven global biopharmaceutical company with an advancing pipeline of innovative products, and Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug discovery company, have entered a new strategic collaboration to combine Insilico’s computational services and AI with invoX’s drug discovery, development and data science capabilities. The aim of the collaboration is to enhance research and development activities for invoX by identifying potential novel indications for pipeline assets in oncology.
The collaboration will utilize Insilico’s target discovery engine, PandaOmics, in conjunction with invoX’s own drug research and development expertise, to identify new potential indications of interest for existing assets in invoX’s pipeline. These potential indications will then undergo further investigation.
Insilico’s PandaOmics is an AI-driven target discovery platform that applies deep learning models to identify therapeutic targets associated with a given disease. The system draws from millions of data points to identify the most promising indications and potential drug combinations. It further refines its selection through analysis of attention metrics, discovery trends, relevant data from Key Opinion Leaders, and chemistry databases. invoX will leverage this technology platform for its target discovery activities.
“We are very excited about this partnership that allows us to work closely together with experts from Insilico Medicine to expand our digital science and AI capabilities in research and development,” says Ben Toogood, Chief Executive Officer at invoX. “There is a huge opportunity to enhance drug development through the use of AI and machine learning. We believe that greater use of AI in drug discovery will ultimately lead to more breakthrough innovations in a shorter time, which will enable us to better serve the needs of patients.”
“The collaboration with invoX is a great opportunity for Insilico to advance the state of the art of artificial intelligence itself and apply it in a way that amplifies the creativity of human experts,” says Alex Zhavoronkov, PhD, founder and Chief Executive Officer of Insilico Medicine. “AI needs to learn from every type of data set that subject matter experts find valuable and that requires the type of close interaction between multiple disciplines we see in this partnership.”
AI models arising from the collaboration will be applied to a range of use cases of which the first two are in execution. The companies are taking a platform approach to AI where a set of large models are trained for multiple tasks. This will allow new projects and use cases to be initiated on a continuous basis throughout the multi-year collaboration between the companies.
About invoX Pharma
invoX Pharma is a research-driven global biopharmaceutical company using next-generation technology platforms to discover and develop innovative medicines that can change the lives of people around the world. The company aspires to improve people’s lives by creating access to innovative medicines that address their unmet healthcare needs. Incorporated in March 2021, invoX has a core focus on oncology and respiratory therapeutics, with R&D, Clinical Development and Business Development activities in the UK, EU and US. invoX is a wholly owned subsidiary of Sino Biopharm, a global top 40 pharmaceutical company with more than 24,000 employees. For further information about invoX Pharma, please visit:
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. For further information about Insilico Medicine, please visit: www.insilico.com/
